匹多莫德对慢性丙型肝炎患者免疫功能的影响

Effects of pidotimod on immune function of patients with chronic hepatitis C

目的探讨匹多莫德对慢性丙型肝炎患者免疫功能的影响。方法12例健康人群为健康对照组,46例为丙肝治疗组,治疗组口服匹多莫德。分别取健康对照组和丙肝治疗组治疗前后血清,采用双抗体酶联分析法检测INF-γ、IL-2、IL-4和IL-6,采用流式细胞仪观察T淋巴细胞亚群变化(CD4+、CD8+和 CD4+／CD8+)。结果治疗组治疗前较对照组IL-2、IL-4、IL-6有明显增高(P<0．05),CD4+细胞数下降,CD8+细胞数增高,CD4+／CD8+比值下降(P<0．01);治疗组治疗后较治疗前INF-γ、IL-2有明显增高(P<0．05),CD4+细胞数增高,CD8+细胞数下降,CD4+／CD8+比值增高(P<0．05)。结论匹多莫德明显提高丙肝患者的免疫功能,为丙型肝炎的治疗提供了有效的辅助。

Objective To investigate the effects of Pidotimod on the immune function in patients with chronic hepatitis C. Methods cases were divided into control and experimental groups： 12 cases of healthy individuals and 46 cases of patients with chronic hepatitis C. Pidotimod of different doses was taken orally in experimental group, and serum levels of INF-γ IL-2, IL-4 and IL-6 were measured by ELISA before and after pidotimod treatment. T lymphocyte subsets of peripheral blood were detected by flow cytometry. Results Compared with control group, serum levels of IL-2 , IL-4 and IL-6 were increased significantly（P 〈 0.05） and CD4^＋ T cells as well as CD4^＋/CD8^＋ ratio（P 〈 0.01） were decreased in experimental group before treatment, and serum levels of INF-γ and IL-2 were significantly increased（P 〈 0.05） and CD4^＋ T ceils as well as CD4^＋/CD8^＋ ratio were also increased markedly（P 〈 0.05） in experimental group post-treatment compared with pretreatment. Conclusion Pidotimod can improve the immune function of patients with chronic hepatitis C, and it provides a subsidiary treatment for the patients with chronic hepatitis C.